Slow Bureaucracy Drives Indian Drug Makers Abroad For Approvals
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers complain their government takes too long to approve clinical trials, leading many of them to go to other countries for faster clearance. Piramal Life Sciences said it turned to Canada after waiting seven months for approval to conduct a trial and got Health Canada's approval within 28 days. Swati Piramal, director of the parent Piramal Group, said India's drug-regulation system is archaic and blocks efforts by Indian drug makers to use their home country to a competitive advantage. Part of the problem stems from insufficiently informed bureaucrats at the regulatory agency. (Click here for more - a subscription may be required